• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.

作者信息

Esposito Susanna, D'Ambrosio Lia, Tadolini Marina, Schaaf H Simon, Caminero Luna Josè, Marais Ben, Centis Rosella, Dara Masoud, Matteelli Alberto, Blasi Francesco, Migliori Giovanni Battista

机构信息

Pediatric Highly Intensive Care Unit, Dept of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy These authors contributed equally.

World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy These authors contributed equally.

出版信息

Eur Respir J. 2014 Sep;44(3):811-5. doi: 10.1183/09031936.00060414. Epub 2014 May 15.

DOI:10.1183/09031936.00060414
PMID:24833763
Abstract
摘要

相似文献

1
ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.欧洲呼吸学会/世界卫生组织结核病咨询委员会对一名儿童广泛耐药结核病管理的援助：使用德拉马尼的同情用药案例研究
Eur Respir J. 2014 Sep;44(3):811-5. doi: 10.1183/09031936.00060414. Epub 2014 May 15.
2
ERS/WHO Tuberculosis Consilium assistance in extensively drug-resistant tuberculosis.欧洲呼吸学会/世界卫生组织结核病咨询委员会对广泛耐药结核病的援助。
Eur Respir J. 2015 Jan;45(1):294-5. doi: 10.1183/09031936.00107814.
3
Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?贝达喹啉和德拉马尼在耐多药结核病患儿中的应用：何为 QTc 延长？
Pediatr Infect Dis J. 2020 Jun;39(6):512-513. doi: 10.1097/INF.0000000000002601.
4
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.利奈唑胺治疗下耐多药和广泛耐药结核病患者的同情用药早期结果。
Eur Respir J. 2017 Jul 27;50(1). doi: 10.1183/13993003.00311-2017. Print 2017 Jul.
5
Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal.应对广泛耐药结核病疫情：奖章背后的公共卫生工作
Eur Respir J. 2015 Jan;45(1):292-4. doi: 10.1183/09031936.00134114.
6
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.贝达喹啉和德拉马尼联合治疗 5 例广泛耐药肺结核患者。
Emerg Infect Dis. 2017 Oct;23(10):1718-21. doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.
7
Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.实地记录：2017年美国在广泛耐药结核病同情用药项目下获取地拉曼尼的情况
MMWR Morb Mortal Wkly Rep. 2018 Sep 7;67(35):996-997. doi: 10.15585/mmwr.mm6735a6.
8
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.治疗药物监测在结核病与艾滋病病毒合并感染的个体化药物剂量及暴露量测量中的作用。
Eur Respir J. 2015 Feb;45(2):571-4. doi: 10.1183/09031936.00157914.
9
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.治疗药物监测在结核病与艾滋病病毒合并感染患者个体化药物剂量及暴露量测定中的作用
Eur Respir J. 2015 Feb;45(2):569-71. doi: 10.1183/09031936.00142614.
10
Timing is everything for compassionate use of delamanid.对于德拉马尼的同情用药而言，时机至关重要。
Nat Med. 2015 Mar;21(3):211. doi: 10.1038/nm.3823.

引用本文的文献

1
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.甘伏伯雷，一种首创的亮氨酰 tRNA 合成酶抑制剂，用于利福平敏感型肺结核：一项 2a 期开放标签、随机试验。
Nat Med. 2024 Mar;30(3):896-904. doi: 10.1038/s41591-024-02829-7. Epub 2024 Feb 16.
2
Design, Synthesis and Antimicrobial Evaluation of New -(1-Hydroxy-1,3-dihydrobenzo[][1,2]oxaborol-6-yl)(hetero)aryl-2-carboxamides as Potential Inhibitors of Mycobacterial Leucyl-tRNA Synthetase.新型 -(1-羟基-1,3-二氢苯并[][1,2]氧杂硼烷-6-基)(杂)芳基-2-羧酰胺的设计、合成与抗菌评价作为分枝杆菌亮氨酰-tRNA 合成酶潜在抑制剂。
Int J Mol Sci. 2023 Feb 2;24(3):2951. doi: 10.3390/ijms24032951.
3
Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?
儿童结核病管理：全球挑战还是突破？
Children (Basel). 2022 Jul 27;9(8):1120. doi: 10.3390/children9081120.
4
Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.含德拉马尼方案与耐多药结核病：系统评价和荟萃分析。
Int J Infect Dis. 2022 Nov;124 Suppl 1(Suppl 1):S90-S103. doi: 10.1016/j.ijid.2022.02.043. Epub 2022 Mar 2.
5
Linezolid resistance in isolates at a tertiary care centre in Mumbai, India.印度孟买一家三级护理中心 分离株的利奈唑胺耐药性。
Indian J Med Res. 2021 Jul;154(1):85-89. doi: 10.4103/ijmr.IJMR_1168_19.
6
Multidisciplinary management of difficult-to-treat drug resistant tuberculosis: a review of cases presented to the national consilium in Uganda.难治性耐药结核病的多学科管理：乌干达国家咨询委员会提交病例的回顾。
BMC Pulm Med. 2021 Jul 10;21(1):220. doi: 10.1186/s12890-021-01597-1.
7
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.儿童耐多药和广泛耐药结核病的治疗：贝达喹啉和德拉马尼的作用
Microorganisms. 2021 May 17;9(5):1074. doi: 10.3390/microorganisms9051074.
8
Curving Tuberculosis: Current Trends and Future Needs.《结核病的变迁：当前趋势与未来需求》。
Ann Glob Health. 2019 Jan 22;85(1):5. doi: 10.5334/aogh.2415.
9
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.地拉曼尼与贝达喹啉治疗儿童耐多药和广泛耐药结核病：一项系统评价
J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16.
10
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.利奈唑胺治疗下耐多药和广泛耐药结核病患者的同情用药早期结果。
Eur Respir J. 2017 Jul 27;50(1). doi: 10.1183/13993003.00311-2017. Print 2017 Jul.